Journal of Medicinal Chemistry · 1999 · 88 citations · 18 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyMolecular PharmacologyStructure-activity RelationshipsEnzyme InhibitionHeterocyclic ChemistryLigand BindingPotency OptimizationTyrosine Kinase InhibitorsEgfr InhibitionEpidermal Growth Factor Receptor InhibitionHeteroaromatic CompoundsIndole ChemistrySelective Tyrosine Kinase InhibitorsSubstituent OptimizationTyrosine Kinase InhibitionTyrosine Kinase Receptors
Several elaborations of the fundamental anilinopyrimidine pharmacophore have been reported as potent and selective inhibitors of the epidermal growth factor receptor (EGFr) tyrosine kinase. This paper reports on a series of inhibitors whereby some 6,5-bicyclic heteroaromatic systems were fused through their C-2 and C-3 positions to this anilinopyrimidine pharmacophore. Although the resulting tricycles did not produce the enormous potency of some of the (5/6),6,6-bicyclic systems, the best of them had IC(50)s for the EGFr TK around 1 nM. Investigation of 4-position side chains in the indolopyrimidines confirmed that m-bromoaniline was an optimal substituent for potency. Investigation of substitution within the C-(benzo)ring of benzothienopyrimidines confirmed that introduction of an extra ring can change sharply the effects of substituents when compared to similar bicyclic nuclei, and only two substituents were found which even moderately enhanced inhibitory activity over the parent compound for this series.
18
Alexander J. Bridges, Hairong Zhou, Donna R. Cody et al. · Journal of Medicinal Chemistry · 1996 · 322 citations · Full text
EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma
Caterina Messa, Francesco Paolo Russo, Maria Gabriella Caruso et al. · Acta Oncologica · 1998 · 250 citations · Full text